Latest news with #PlaqueIQ
Business Wire
2 days ago
- Business
- Business Wire
Elucid's PlaqueIQ™ Image Analysis Software Included in EviCore Coverage Guidelines
BOSTON--(BUSINESS WIRE)-- Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, today announced that EviCore, a radiology benefit manager, has updated its cardiac imaging guidelines to include coverage of coronary computed tomography angiography (CTA) plaque quantification (see pages 82-24), effective October 1, 2025. EviCore's updated coverage guidelines for CPT Codes 0623T-0624T could extend non-invasive plaque analysis to more individuals and help physicians gain a clearer understanding of each patient's coronary plaque. Elucid's flagship PlaqueIQ™ coronary plaque assessment technology falls within the coverage guidelines. PlaqueIQ delivers automated quantification and classification of plaque morphology, and is uniquely capable of identifying and quantifying lipid-rich necrotic core, the plaque type most strongly associated with cardiovascular risk. Share PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology. PlaqueIQ delivers automated quantification and classification of plaque morphology, and is uniquely capable of identifying and quantifying lipid-rich necrotic core, the plaque type most strongly associated with cardiovascular risk. The software is designed to help physicians prioritize and personalize treatment based on actual coronary artery disease, rather than population-based risk. This technology supports physicians in evaluating patients' risk of future cardiac events, such as heart attack and stroke, and enables the development of personalized care pathways informed by each patient's individual plaque characteristics. 'EviCore's updated coverage guidelines demonstrate the increased understanding of the value of non-invasive coronary plaque analysis using Elucid PlaqueIQ,' said Elucid CEO Kelley Huang, PhD. 'This important milestone is one more step towards our vision of a future where cardiac care is personalized patient care as opposed to risk factor and population-based care.' EviCore's updated commercial coverage guidelines follow a new CMS rule that went into effect January 1, 2025, which doubled the amount paid to hospitals and outpatient clinics who perform cardiac CT scans from $175 to $357.13. This has allowed more hospitals, particularly those in non-urban areas, to be able to offer this service, reducing disparities in care. In late 2024, five of the seven Medicare Administrative Contractors (MACs) issued decisions to extend coverage of Elucid's PlaqueIQ AI-enabled quantitative coronary plaque analysis software, making it available to over 70 percent of eligible Medicare patients across the United States. Elucid will showcase the importance of plaque morphology quantification and classification at the lesion level and why morphology based on histology is the gold standard for plaque characterization at the 20 th Annual Meeting of the Society of Cardiovascular Computed Tomography (SCCT 2025), in Montréal from July 17-20, 2025. About Elucid Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ™ image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit
Business Wire
6 days ago
- Business
- Business Wire
Elucid to Showcase PlaqueIQ™ at SCCT 2025
BOSTON--(BUSINESS WIRE)-- Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, will be featured along with its PlaqueIQ™ image analysis software at the 20 th Annual Meeting of the Society of Cardiovascular Computed Tomography (SCCT 2025), to be held July 17-20 at Palais des Congrès de Montréal. PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology rather than subjective CCTA visual estimates. The software is designed to help physicians prioritize and personalize treatment based on actual disease. Share Elucid CEO Kelly Huang, PhD, will participate in the Novel Technologies keynote session, which will be held on Friday, July 18 from 5:05 to 6:15 p.m. ET in room 210 B/F. Kelly's presentation, 'Lesion, vessel, patient, population. Anatomy, physiology, morphology: A complete picture,' will detail the importance of plaque morphology quantification and classification at the lesion level and why morphology based on histology is the gold standard for plaque characterization. Elucid will also host a breakfast symposium, ' From Lesion Detail to the Patient: Getting the Entire Story with Anatomy, Physiology and Morphology,' Friday, July 18 from 7 to 7:50 a.m. ET in room 511 C/F. The session will feature two of the preeminent experts in preventative cardiology and CCTA-derived plaque morphology: Dr. Amir Ahmadi, associate professor of medicine and cardiology director, Inpatient Cardiology at Mount Sinai Fuster Heart at Morningside and Elucid lead scientific advisor, and Dr. Mark D. Berlacher, clinical cardiologist at The Christ Hospital. The session will provide a deep dive into several plaque cases using Elucid's software and share how these findings influence treatment pathways. The program will also explore FFR CT features on an investigational basis. 1 'The cases we will present at SCCT 2025 demonstrate the importance of moving beyond the vessel level to assess plaque at the lesion level,' said Dr. Berlacher. 'Having detailed information about the amount and type of plaque at the lesion level, including lipid rich necrotic core, can help drive treatment decisions and help physicians get ahead of potentially deadly cardiac events.' In addition to its participation in the SCCT 2025 program, Elucid will hold three dinner presentations and discussions on Thursday, July 17, Friday, July 18, and Saturday, July 19. The presentation, 'CT-Guided Treatment of Coronary Artery Disease: A Step Toward Precision Medicine,' features Dr. Ahmadi, and will also include product demos. Attendees may also participate in hands-on demos of Elucid's flagship PlaqueIQ image analysis software, as well as its FFR CT plaque-based algorithm (in development), in Booth 215 during exhibit hall hours. Additionally, Amy Pyke, Elucid's senior vice president of Market Access, will host reimbursement Q&A office hours in the booth on Friday from 11:30 a.m. to 12:30 p.m. ET and Saturday from 12:30 to 1:30 p.m. ET. PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology rather than subjective CCTA visual estimates. PlaqueIQ quantifies and classifies plaque morphology based on ground-truth histology, the gold standard for characterization of plaques. The software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk. About Elucid Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ™ image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit
Business Wire
07-07-2025
- Business
- Business Wire
Elucid Appoints Dr. Robert Pelberg as New Senior Vice President of Medical Affairs
BOSTON--(BUSINESS WIRE)-- Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has named Dr. Robert 'Bob' Pelberg as its new senior vice president of medical affairs. A highly accomplished cardiologist and nationally recognized expert in cardiovascular computed tomography angiography (CCTA), Dr. Pelberg brings to Elucid decades of clinical experience and a deep understanding of advanced imaging technologies and clinical research. In his new role, he will help shape and execute the company's clinical and research strategies and will lead the company's clinical operations quality efforts, ensuring compliance to the highest clinical quality and regulatory standards. 'Dr. Pelberg's appointment marks a critical step in Elucid's mission to deliver clinically valuable and scientifically rigorous tools to physicians." Share Dr. Pelberg's hiring comes at a pivotal moment for Elucid, as it accelerates both its clinical research strategy and commercial growth of its flagship product PlaqueIQ TM image analysis software. PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology rather than subjective CCTA visual estimates. PlaqueIQ quantifies and classifies plaque morphology based on ground-truth histology, the gold standard for characterization of plaques. The software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk. 'Dr. Pelberg's appointment marks a critical step in Elucid's mission to deliver clinically valuable and scientifically rigorous tools to physicians. He will play a key role in expanding awareness of the company's software and key features within the medical community—engaging with clinicians, guiding study design, and articulating the clinical value of Elucid's histology-based technology in improving cardiovascular care, with our plaque analysis software today and our FFR-CT product in the near future,' said Kelly Huang, CEO of Elucid. 'Together, we are committed to helping align product development with real-world clinical needs, ultimately enhancing the impact of Elucid's work in transforming diagnostics for coronary artery disease.' Dr. Pelberg is board certified in cardiovascular diseases, cardiac CT angiography, nuclear cardiology and echocardiography. He is a fellow of the American College of Cardiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology and the Society of Cardiovascular Computed Tomography. He is also the author and co-author of numerous books as well as clinical publications in the field of cardiac CT. With extensive leadership experience directing cardiovascular service line clinical operations, he most recently served as a clinical cardiologist and advanced cardiac imager at The Christ Hospital Heart and Vascular Institute. 'As physicians, we know the importance of having a clear understanding of each patient's coronary plaque and how that impacts their risk of future cardiac events, including heart attack and stroke, as well as how to care for each individual based on their own plaque assessment. I share Elucid's vision of a future where physicians will be able to incorporate patient specific plaque characteristics to create personalized care pathways in coronary artery disease that can ultimately help reverse the prevalence of heart attack and stroke,' said Dr. Pelberg. 'I look forward to contributing to the company's mission and helping deliver on that goal.' About Elucid Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ TM image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit
